Skip to main content

COVID-19 trial protocols

Research into COVID-19 is exploding, as it needs to, and this includes randomised trials.  Between 23rd of January and 8th March 2020 there were 382 registered COVID-19 trials. Almost all of those were in China but the virus is now global and trials will move with it.

Researchers need to know about these trials, and they need to know quickly.  

Trials are therefore implementing a new, simplified process for handling COVID-19 trial protocols which is must faster and much simpler for authors. Please visit trialsjournal.biomedcentral.com/covid-19 for more information.

Page 3 of 4

  1. Objectives: The Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and morta...

    Authors: Anne Marie Rosendahl Madsen, Frederik Schaltz-Buchholzer, Thomas Benfield, Morten Bjerregaard-Andersen, Lars Skov Dalgaard, Christine Dam, Sisse Bolm Ditlev, Gulia Faizi, Isik Somuncu Johansen, Poul-Erik Kofoed, Gitte Schultz Kristensen, Ellen Christine Leth Loekkegaard, Christian Backer Mogensen, Libin Mohamed, Anne Ostenfeld, Emilie Sundhaugen Oedegaard…

    Citation: Trials 2020 21:799

    Content type: Letter

    Published on:

  2. In some patients, acute, life-threatening respiratory injury produced by viruses such as SARS-CoV and other viral pneumonia are associated with an over-exuberant cytokine release. Elevated levels of blood IL-6...

    Authors: Antonio F. Caballero Bermejo, Belén Ruiz-Antorán, Ana Fernández Cruz, Elena Diago Sempere, Alejandro Callejas Díaz, Elena Múñez Rubio, Cristina Avendaño-Solá, Antonio Ramos Martínez and Aránzazu Sancho López

    Citation: Trials 2020 21:794

    Content type: Letter

    Published on:

  3. We investigate the effects of Licorice (Glycyrrhiza glabra L.) root extract, an anti-inflammatory natural medicine, compared to the usual therapeutic regimen on clinical symptoms and laboratory signs in patients ...

    Authors: Omid Safa, Mehdi Hassani-Azad, Mehdi Farashahinejad, Parivash Davoodian, Habib Dadvand, Soheil Hassanipour and Mohammad Fathalipour

    Citation: Trials 2020 21:790

    Content type: Letter

    Published on:

  4. 1- To compare the effectiveness of 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline and a novel solution Neem extract (Azardirachta indica) in reducing intra-oral viral load in COVID-19 positive p...

    Authors: Farhan Raza Khan, Syed Murtaza Raza Kazmi, Najeeha Talat Iqbal, Junaid Iqbal, Syed Tariq Ali and Syed Akbar Abbas

    Citation: Trials 2020 21:785

    Content type: Letter

    Published on:

  5. This study aims to demonstrate the positive effects on oxygenation of flow-controlled ventilation compared to conventionally ventilated patients in patients suffering from Acute respiratory distress syndrome (...

    Authors: Stefan Roehrig, Ali Ait Hssain, Nabil Al Hamid Shallik, Ingi Mohamed A. Elsaid, Salma Faisal Mustafa, Osama A. M. Smain, Ashraf Abdulla Molokhia and Marcus D. Lance

    Citation: Trials 2020 21:781

    Content type: Letter

    Published on:

  6. The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the cu...

    Authors: Rosario Garcia-Vicuña, Francisco Abad-Santos, Isidoro González-Alvaro, Francisco Ramos-Lima and Jesús Sanz Sanz

    Citation: Trials 2020 21:772

    Content type: Letter

    Published on:

  7. The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral di...

    Authors: Stefano Barco, Roland Bingisser, Giuseppe Colucci, André Frenk, Bernhard Gerber, Ulrike Held, Francois Mach, Lucia Mazzolai, Marc Righini, Thomas Rosemann, Tim Sebastian, Rebecca Spescha, Stefan Stortecky, Stephan Windecker and Nils Kucher

    Citation: Trials 2020 21:770

    Content type: Letter

    Published on:

  8. To assess the effect of anticoagulation with bivalirudin administered intravenously on gas-exchange in patients with COVID-19 and respiratory failure using invasive mechanical ventilation.

    Authors: Nadir Kharma, Stefan Roehrig, Ahmed Atef Shible, Moustafa Sayed Elshafei, Dema Osman, Ingi Mohamed Elsaid, Salma Faisal Mustafa, Asjad Aldabi, Osamah A.M. Smain and Marcus D. Lance

    Citation: Trials 2020 21:769

    Content type: Letter

    Published on:

  9. To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. ...

    Authors: Lamis Kaddam, Rasha Babiker, Sara Ali, Shahinaz Satti, Nour Ali, Maha Elamin, Mowaia Mukhtar, Mustafa Elnimeiri and Amal Saeed

    Citation: Trials 2020 21:766

    Content type: Letter

    Published on:

  10. Tocilizumab is a humanized monoclonal antibody which targets and inhibits interleukin-6 (IL-6) and has demonstrated efficacy in treating diseases associated with hyper-inflammation. Data are suggestive of toci...

    Authors: Aoife Cotter, Deborah Wallace, Cormac McCarthy, Eoin Feeney, Lorraine O’Neill, John Stack, Geraldine McCarthy, Rabia Hussain, Elena Alvarez Barco, Peter Doran and Patrick Mallon

    Citation: Trials 2020 21:758

    Content type: Letter

    Published on:

  11. To evaluate the effect of the combination of hydroxychloroquine (HCQ) and standard personal protective equipment (PPE) compared to the use of standard personal protective equipment alone on the proportion of l...

    Authors: Bharath Kumar Tirupakuzhi Vijayaraghavan, Vivekanand Jha, Dorrilyn Rajbhandari, Sheila Nainan Myatra, Oommen John, Arpita Ghosh, Abhinav Bassi, Sumaiya Arfin, Mallikarjuna Kunigari, Rohina Joshi, Lachlan Donaldson, Naomi Hammond and Balasubramanian Venkatesh

    Citation: Trials 2020 21:754

    Content type: Letter

    Published on:

  12. The first case of a coronavirus 2019 (COVID-19) infection in a Sri Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid increase of personnel contracting COVID-19 in a naval...

    Authors: Madunil A. Niriella, Dileepa S. Ediriweera, Arjuna P. De Silva, Ranjan Premarathne, Priyantha Balasooriya, Kaluthanthri D. Duminda, Neelika G. Malavige, Kamani Wanigasuriya, Sarath Lekamwasam, Senanayake A. Kularathne, Sisira Siribaddana, Hithanadura J. de Silva and Saroj Jayasinghe

    Citation: Trials 2020 21:748

    Content type: Study protocol

    Published on:

  13. To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically vent...

    Authors: Pär Ingemar Johansson, Morten Bestle, Peter Søe-Jensen, Klaus Tjelle Kristiansen, Jakob Stensballe, Niels Erikstrup Clausen and Anders Perner

    Citation: Trials 2020 21:746

    Content type: Letter

    Published on:

  14. The aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia.

    Authors: Luis Patricio Maskin, Gabriel Leonardo Olarte, Fernando Palizas Jr, Agostina E. Velo, María Fernanda Lurbet, Ignacio Bonelli, Natalio D. Baredes and Pablo Oscar Rodríguez

    Citation: Trials 2020 21:743

    Content type: Letter

    Published on:

  15. This study aims to determine the protection provided by Shenfu injection (a traditional Chinese medicine) against development of organ dysfunction in critically ill patients with coronavirus disease 2019 (COVI...

    Authors: Zong-Yu Wang, Shou-Zhi Fu, Liang Xu, Shu-Sheng Li, Ke-Jian Qian, Xian-Di He, Guo-Chao Zhu, Liang-Hai Li, Jun Zhang, Wen-Fang Li, Bing-Yu Qin, Chen-Liang Zhou and Peng-Lin Ma

    Citation: Trials 2020 21:738

    Content type: Letter

    Published on:

  16. Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticost...

    Authors: Jonathan A. C. Sterne, Janet Diaz, Jesús Villar, Srinivas Murthy, Arthur S. Slutsky, Anders Perner, Peter Jüni, Derek C. Angus, Djillali Annane, Luciano Cesar Pontes Azevedo, Bin Du, Pierre-Francois Dequin, Anthony C. Gordon, Cameron Green, Julian P. T. Higgins, Peter Horby…

    Citation: Trials 2020 21:734

    Content type: Letter

    Published on:

  17. To assess the hypothesis that an adjunctive therapy with methylprednisolone and unfractionated heparin (UFH) or with methylprednisolone and low molecular weight heparin (LMWH) are more effective in reducing an...

    Authors: Stefano Busani, Martina Tosi, Pasquale Mighali, Paola Vandelli, Roberto D’Amico, Marco Marietta, Francesco Forfori, Abele Donati, Gilda Cinnella, Amato De Monte, Daniela Pasero, Giacomo Bellani, Carlo Tascini, Giuseppe Foti, Marco Ranieri and Massimo Girardis

    Citation: Trials 2020 21:724

    Content type: Letter

    Published on:

  18. The primary aim of the present study is to examine the efficacy of an online intervention for poor sleep in the context of an ongoing stressful major life event, by assessing if this intervention can reduce in...

    Authors: Greg J. Elder, Pamela Alfonso-Miller, William C. M. Atkinson, Nayantara Santhi and Jason G. Ellis

    Citation: Trials 2020 21:704

    Content type: Letter

    Published on:

  19. To investigate the potential efficacy of Nigella sativa (NS) oil supplementation on the outcomes of patients with mild Coronavirus Disease 2019 (COVID-19).

    Authors: Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, Meshari M. Alhamdan, Reem A. Almalki and Tariq A. Madani

    Citation: Trials 2020 21:703

    Content type: Letter

    Published on:

  20. To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg or...

    Authors: Javed Akram, Shehnoor Azhar, Muhammad Shahzad, Waqas Latif and Khalid Saeed Khan

    Citation: Trials 2020 21:702

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:733

  21. • Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19.

    Authors: Miguel Rodríguez-Rubio, Juan Carlos Figueira, Darío Acuña-Castroviejo, Alberto M. Borobia, Germaine Escames and Pedro de la Oliva

    Citation: Trials 2020 21:699

    Content type: Letter

    Published on:

  22. Stage 1: To evaluate the safety and efficacy of candidate agents as add-on therapies to standard of care (SoC) in patients hospitalised with COVID-19 in a screening stage.

    Authors: Tom Wilkinson, Rupert Dixon, Clive Page, Miles Carroll, Gareth Griffiths, Ling-Pei Ho, Anthony De Soyza, Timothy Felton, Keir E. Lewis, Karen Phekoo, James D. Chalmers, Anthony Gordon, Lorcan McGarvey, Jillian Doherty, Robert C. Read, Manu Shankar-Hari…

    Citation: Trials 2020 21:691

    Content type: Letter

    Published on:

  23. To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: de...

    Authors: Ing Ni Lu, Spoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, Edward Banham-Hall, Sonakshi Kadyan, Simon Bond, Sam Norton, Andrew Cope, James Galloway, Frances Hall, David Jayne, Ian B. Wilkinson and Joseph Cheriyan

    Citation: Trials 2020 21:690

    Content type: Letter

    Published on:

  24. Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion a...

    Authors: Oriana Nanni, Pierluigi Viale, Bernadette Vertogen, Claudia Lilli, Chiara Zingaretti, Caterina Donati, Carla Masini, Manuela Monti, Patrizia Serra, Roberto Vespignani, Veruska Grossi, Annibale Biggeri, Emanuela Scarpi, Francesca Galardi, Lucia Bertoni, Americo Colamartini…

    Citation: Trials 2020 21:689

    Content type: Study protocol

    Published on:

  25. The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome c...

    Authors: Berta Grau-Pujol, Daniel Camprubí, Helena Marti-Soler, Marc Fernández-Pardos, Caterina Guinovart and Jose Muñoz

    Citation: Trials 2020 21:688

    Content type: Letter

    Published on:

  26. The trial objective is to determine if Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) is clinically effective compared to standard oxygen therapy in patients with confirmed or susp...

    Authors: Gavin D. Perkins, Keith Couper, Bronwen Connolly, J. Kenneth Baillie, Judy M. Bradley, Paul Dark, Anthony De Soyza, Ellen Gorman, Alasdair Gray, Louisa Hamilton, Nicholas Hart, Chen Ji, Ranjit Lall, Nicola McGowan, Scott Regan, Anita K. Simonds…

    Citation: Trials 2020 21:687

    Content type: Letter

    Published on:

  27. To assess the efficacy of local intranasal treatment with budesonide (nasal irrigation), in addition to olfactory rehabilitation, in the management of loss of smell in COVID-19 patients without signs of severi...

    Authors: Mary Daval, Alain Corré, Clement Palpacuer, Juliette Housset, Guillaume Poillon, Michael Eliezer, Benjamin Verillaud, Dorsaf Slama, Denis Ayache, Philippe Herman, Clement Jourdaine, Camille Hervé, Wissame El Bakkouri, Dominique Salmon and Charlotte Hautefort

    Citation: Trials 2020 21:666

    Content type: Letter

    Published on:

  28. Objective 1: To determine if it is feasible to conduct an RCT of online Sudarshan Kriya Yoga (SKY) for frontline hospital and long-term care home staff under the constraints imposed by the COVID-19 pandemic and n...

    Authors: Ka Sing Paris Lai, Christine Watt, Emily Ionson, Imants Baruss, Cheryl Forchuk, Javeed Sukhera, Amer M. Burhan and Akshya Vasudev

    Citation: Trials 2020 21:648

    Content type: Letter

    Published on:

  29. Primary Objective: To determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily reduces microbiologically confirmed COVID-19 among front line health care workers at...

    Authors: Julie K. Wright, Darrell H. S. Tan, Sharon L. Walmsley, Jennifer Hulme, Erin O’Connor, Carolyn Snider, Ivy Cheng, Adrienne K. Chan, Bjug Borgundvaag, Shelley McLeod, Michael H. Gollob, Rosemarie J. Clarke, Linda Dresser, Fatima Haji, Tony Mazzulli, Samira Mubareka…

    Citation: Trials 2020 21:647

    Content type: Letter

    Published on:

  30. To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-...

    Authors: Justin T. Denholm, Joshua Davis, David Paterson, Jason Roberts, Susan Morpeth, Thomas Snelling, Dominica Zentner, Megan Rees, Matthew O’Sullivan, David Price, Asha Bowen and Steven Y. C. Tong

    Citation: Trials 2020 21:646

    Content type: Letter

    Published on:

  31. Citation: Trials 2020 21:639

    Content type: Letter

    Published on:

  32. The aim of this trial is to identify the effect of ambulatory treatment in early COVID-19 disease with hydroxychloroquine on the rate of hospitalization or death in older patients above the age of 64.

    Authors: Siri Göpel, Wolfgang Bethge, Peter Martus, Florian Kreth, Thomas Iftner, Stefanie Joos, Stefanie Döbele, Benjamin Mordmüller, Peter Kremsner, Thomas Ettrich, Thomas Seufferlein, Michael Bitzer and Nisar Malek

    Citation: Trials 2020 21:635

    Content type: Letter

    Published on:

  33. The aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission cri...

    Authors: Miriam Saiz-Rodríguez, Teresa Peña, Lourdes Lázaro, Ángel González, Andrés Martínez, José A. Cordero, Juan T. Vicente, Fernando Richard, María Jesús Coma, Martín de Frutos, Jorge Labrador and Ana Pueyo

    Citation: Trials 2020 21:632

    Content type: Letter

    Published on:

  34. To determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC).

    Authors: Spoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, Edward Banham-Hall, Simon Bond, Elena Hernan-Sancho, Sam Norton, Joseph Cheriyan, Andrew Cope, James Galloway, Frances Hall, David Jayne and Ian B. Wilkinson

    Citation: Trials 2020 21:626

    Content type: Letter

    Published on:

  35. This study will evaluate the main hypothesis that supplementation with vitamins A, B, C, D, and E significantly improves the severity and mortality rate in ICU patients with COVID-19.

    Authors: Mohammad Taghi Beigmohammadi, Sama Bitarafan, Azin Hoseindokht, Alireza Abdollahi, Laya Amoozadeh, Maedeh Mahmoodi Ali Abadi and Morteza Foroumandi

    Citation: Trials 2020 21:614

    Content type: Study protocol

    Published on:

  36. As there is no treatment for COVID-19 with a proven mortality benefit at this moment in the pandemic, supportive management including mechanical ventilation is the core management in an intensive care unit (IC...

    Authors: Atsushi Kawaguchi, Gabrielle Bernier, Jacques Lacroix, Saly El Salti, Matthew P. Cheng, Todd C. Lee, Kosar Khwaja and Philippe Jouvet

    Citation: Trials 2020 21:610

    Content type: Letter

    Published on:

  37. To evaluate the therapeutic effects of ultra-short-wave diathermy (SWD) on COVID-19 pneumonia. The hypothesis is that SWD may minimise pneumonic inflammation and shorten the duration of the time to positive-to...

    Authors: Mohammad Nasb, Zulfiqar Ali Sayed Shah, Liangjiang Huang, Qian Li and Hong Chen

    Citation: Trials 2020 21:609

    Content type: Letter

    Published on:

  38. The primary objectives of the study are:

    Authors: Raquel González, Laura García-Otero, Clara Pons-Duran, Elena Marbán-Castro, Anna Goncé, Elisa Llurba, Maria del Mar Gil, Miguel Ángel Rodríguez-Zambrano, Haily Chen, Máximo Ramírez, Azucena Bardají and Clara Menendez

    Citation: Trials 2020 21:607

    Content type: Letter

    Published on:

  39. To determine whether chemoprophylaxis with hydroxychloroquine versus placebo increases time to contracting coronavirus disease 2019 (COVID-19) in frontline healthcare workers.

    Authors: Carmel M. McEniery, Marie Fisk, Karen Miles, Fotini Kaloyirou, Annette Hubsch, Jane Smith, Ian B. Wilkinson and Joseph Cheriyan

    Citation: Trials 2020 21:604

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:641

  40. Primary objective: Evaluation of the effect of the proton pump inhibitor (PPI) pantoprazole on the absorption of hydroxychloroquine (HCQ).

    Authors: Felicitas Stoll, Antje Blank, Gerd Mikus, David Czock, Kathrin I. Foerster, Simon Hermann, Katja Häußler, Amin Muhareb, Simone Hummler, Johanna Weiss, Jürgen Burhenne and Walter E. Haefeli

    Citation: Trials 2020 21:584

    Content type: Letter

    Published on:

  41. Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy is available and tr...

    Authors: Helena Stockmann, Theresa Keller, Stefan Büttner, Achim Jörres, Detlef Kindgen-Milles, Julius Valentin Kunz, Josef Leebmann, Claudia Spies, Karl Träger, Sascha Treskatsch, Alexander Uhrig, Carsten Willam, Philipp Enghard and Torsten Slowinski

    Citation: Trials 2020 21:577

    Content type: Letter

    Published on:

  42. Primary Objective:

    Authors: Carlos Tornero, Ricardo Vallejo, David Cedeño, Jorge Orduña, Ernesto Pastor, Moncef Belaouchi, Benigno Escamilla, Marisa Laredo and María del Mar Garzando

    Citation: Trials 2020 21:576

    Content type: Letter

    Published on:

  43. In this study, we investigate the effect of hydroxychloroquine on the prevention of Novel Coronavirus Disease (COVID-19) in cancer patients being treated.

    Authors: Abolghasem Allahyari, Hossein Rahimi, Majid Khadem-Rezaiyan, Zahra Mozaheb, Mohsen Seddigh-Shamsi, Alireza Bary, Mostafa Kamandi, Sajad Ataei Azimi, Saeed Eslami HasanAbadi, Alireza Noferesti, Somayeh Sadat Shariatmaghani, Houshang Rafatpanah, Shohreh Khatami, Afshin Jabbar Imani, Hassan Mortazi and Mohammad Moeini Nodeh

    Citation: Trials 2020 21:575

    Content type: Letter

    Published on:

    The Update to this article has been published in Trials 2021 22:349

  44. To assess whether high doses of Low Molecular Weight Heparin (LMWH) (i.e. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients w...

    Authors: Marco Marietta, Paola Vandelli, Pasquale Mighali, Roberto Vicini, Valeria Coluccio and Roberto D’Amico

    Citation: Trials 2020 21:574

    Content type: Letter

    Published on:

  45. Tissue hypoxia is the main cause of multi-organ dysfunction in sepsis. However, effective pharmacological treatments to combat sepsis-induced tissue hypoxia are not available. Emerging experimental and clinica...

    Authors: Constantinos Pantos, Georgia Kostopanagiotou, Apostolos Armaganidis, Athanasios Trikas, Ioulia Tseti and Iordanis Mourouzis

    Citation: Trials 2020 21:573

    Content type: Letter

    Published on:

  46. There is little information about Coronavirus Disease 2019 (COVID-19) management for critically ill patients. Most of these patients develop acute respiratory distress syndrome (ARDS) due to excessive inflamma...

    Authors: Nafiseh Abdolahi, Effat Kaheh, Roghieh Golsha, Behnaz Khodabakhshi, Alireza Norouzi, Mahmoud Khandashpoor, Sima Besharat, Samane Tavassoli, Somayeh Livani, Sadegh Ali Azimi, Mohammad Hadi Gharib, Babak Peivandi, Abdolreza Fazel, Hesamaddin Shirzad-Aski and Gholamreza Roshandel

    Citation: Trials 2020 21:549

    Content type: Letter

    Published on:

  47. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and ...

    Authors: J. P. Desilles, C. Gregoire, C. Le Cossec, J. Lambert, O. Mophawe, M. R. Losser, F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, P. Trouiller and J. Pottecher

    Citation: Trials 2020 21:548

    Content type: Letter

    Published on:

  48. Phase I - To determine the optimal dose of each candidate (or combination of candidates) entered into the platform.

    Authors: Gareth Griffiths, Richard Fitzgerald, Thomas Jaki, Andrea Corkhill, Ellice Marwood, Helen Reynolds, Louise Stanton, Sean Ewings, Susannah Condie, Emma Wrixon, Andrea Norton, Mike Radford, Sara Yeats, Jane Robertson, Rachel Darby-Dowman, Lauren Walker…

    Citation: Trials 2020 21:544

    Content type: Letter

    Published on:

    The Update to this article has been published in Trials 2021 22:487

  49. To assess the safety and therapeutic effects of allogeneic human dental pulp stem cells (DPSCs) in treating severe pneumonia caused by COVID-19.

    Authors: Qingsong Ye, Hua Wang, Xia Xia, Chenliang Zhou, Zhiming Liu, Zun-en Xia, Zhan Zhang, Yang Zhao, Jun Yehenala, Si Wang, Gangqiao Zhou, Ke Hu, Bin Wu, Chu-Tse Wu, Songling Wang and Yan He

    Citation: Trials 2020 21:520

    Content type: Letter

    Published on:

  50. The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and...

    Authors: Pradeesh Sivapalan, Charlotte Suppli Ulrik, Rasmus Dahlin Bojesen, Therese Sophie Lapperre, Josefin Viktoria Eklöf, Kjell Erik Julius Håkansson, Andrea Browatzki, Casper Tidemansen, Jon Torgny Wilcke, Julie Janner, Vibeke Gottlieb, Howraman Meteran, Celeste Porsbjerg, Birgitte Lindegaard Madsen, Mia Moberg, Lars Pedersen…

    Citation: Trials 2020 21:513

    Content type: Letter

    Published on:

    The Update to this article has been published in Trials 2020 21:867